MSAB Announces XAMN Spotlight 2.0
ARLINGTON, Va., 2017-04-27 14:00 CEST (GLOBE NEWSWIRE) --
MSAB, a global leader in forensic technology for mobile device examination, today announced XAMN Spotlight 2.0, a product designed with the needs of the modern investigator in mind. XAMN Spotlight 2.0 is built for finding and analyzing data faster, more efficiently and expediently. MSAB introduces powerful new features to the product, such as search filters. Enhanced views help investigators improve speed and accuracy, a new Source Mode was integrated to verify hex data, the ability to pivot investigations around individual artifacts, and multi-monitor support, make up some of the many upgrades.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/96bfbb14-28b8-447e-841b-9d9d98864061
As the amount of data in smartphones steadily increases, investigators are tasked with sifting through thousands of messages and gigabytes of information to find the relevant facts. This is only getting harder to achieve.
“We know that investigators are an integral part of law enforcement, so continuing to increase their efficiency is critical for future success,” said Joel Bollö, CEO of MSAB. “Spotlight 2.0 is focused on supporting those investigators that know what they are looking for, as well as digital forensic investigators who are interested in the output of a mobile device examination. It combines ease of use, with powerful searching capabilities, and can be efficiently utilized.”
Spotlight is the flagship tool in the new suite of XAMN analysis products from MSAB. Spotlight has evolved to become much more powerful. Spotlight 2.0 includes four different views, each of which displays different aspects of the case.
XAMN Spotlight 2.0. Now more powerful than ever.
- Review of multiple XRY extractions in one application
- Source Mode to allow review of original hex data
- Powerful filter search capabilities
- Power tagging
- Quick views
- Extensive reporting functionality
- Intuitive user interface
The XAMN Spotlight 2.0 lets investigators and specialists quickly identify critical information, whether through a big picture or with precise details. Its power search capabilities allow a user to pull and analyze from huge data sets of mobile evidence.
XAMN Spotlight is simple to use and minimizes the requirement for infrastructure and training. Every investigator can directly take advantage of the power of XAMN Spotlight to solve crimes faster, resulting in financial savings and improved efficiency.
XAMN is a suite of analysis tools designed primarily to help investigators and forensic specialists work more efficiently.
- XAMN Spotlight 2.0 is very flexible, allowing you to scale it according to your organizational needs and requirements.
For more information about MSAB and its products go to www.msab.com
MSAB is a world leader in mobile forensics technology with the aim of extracting and analyzing data from confiscated mobile devices, mainly mobile phones. The company has its own sales offices and sales representatives in Europe, North America, South America, China, Australia and Russia, and together with a number of distributors covers most of the world. The company's proprietary products have become a de facto standard in the field and are used for securing evidence in over 100 countries. The products are complemented by a wide range of training courses, with the opportunity to become certified in a forensically sound method of extracting data from mobile devices. Customers are primarily authorities involved in performing criminal investigations, and include police, military and customs. MSAB is listed on NASDAQ Stockholm under the ticker symbol: MSAB B.
46 85 99 22 520
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25 | Pressemelding
YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p
Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30 | Pressemelding
CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC. Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S. DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa
Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12 | Pressemelding
SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15 | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations se
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16 | Pressemelding
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.
New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris17.10.2017 06:01 | Pressemelding
New Site Expands Headwear and Apparel Offering with Immersive, Omnichannel Experience NEWTOWN, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, and New Era, a global headwear brand rooted in sports, today announced the launch of New Era's first direct-to-consumer website, neweracap.com. New Era's B2B business remains strong, and the company is now putting an emphasis on selling its products directly to customers and expanding its offering into the lifestyle market. The new site offers products for seasoned athletes and sports fans, as well as street and lifestyle consumers. "In an age where businesses cannot tolerate lengthy, scope changing technology projects, EPAM quickly established themselves as the standout partner for us to tackle this ambitious initiative," said Lorenz Gan, Global Vice President, Information Technology, New Era. "Whilst this p
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom